Please login to the form below

Not currently logged in
Email:
Password:

Chiesi extends research deal with NiKem

Chiesi Farmaceutici is to extend its research collaboration with NiKem Research, focused on developing treatments within the respiratory therapeutic area

Chiesi Farmaceutici is to extend its research collaboration with NiKem Research, focused on developing treatments within the respiratory therapeutic area.

The two companies have been working together since 2001, with the new deal extending their efforts until 2014.

The collaboration will see NiKem continue its work providing services such as design, lead optimisation and biochemical pharmacology within different therapeutic areas on a fee-for-service basis.

Italy-based Chiesi specialises in products for respiratory pathologies, special care medicine and cardiovascular diseases, with the extended NiKem agreement focused on respiratory illnesses such as asthma and COPD.

Giuseppe Giardina, CEO of NiKem, said: "The scientific and business relationship with Chiesi is rock solid and the current extension follows 10 years of continuous success for both parties in collaborating to identify novel compounds eligible to candidate status for clinical development."

6th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics